Cohance Lifesciences
India
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
✓ FDA Inspections (6)
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (6)
Quick Facts: Cohance Lifesciences
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- India
- Website
- https://www.cohance.com/
- Modalities
- Small Molecule API, ADC / Bioconjugation, Peptides & Oligos
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Cohance Lifesciences
Cohance Lifesciences is a contract development and manufacturing organization (CDMO). Capabilities: Small Molecule API, ADC / Bioconjugation, Peptides & Oligos. 5 manufacturing sites registered with the U.S. FDA and Health Canada. Website: https://www.cohance.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Cohance Lifesciences FDA Inspection History
2025-09
2025-03
2024-07
2024-02
2023-04
2023-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-09-11 |
Cohance Lifesciences Limited
Krishna District
Company-level
|
Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2025-03-07 |
Cohance Lifesciences Limited
Medchal-Malkajgiri
Company-level
|
Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
| 2024-07-12 |
Cohance Lifesciences Limited
Rangareddy District
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2024-02-23 |
Cohance Lifesciences Limited
Sangareddy
Company-level
|
Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2023-04-14 |
Cohance Lifesciences Limited
Ankleshwar
Company-level
|
Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2023-01-26 |
Cohance Lifesciences Limited
Hyderabad
Company-level
|
Bioresearch Monitoring | No | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Oct 31, 2026
Cohance Lifesciences FDA 483 Findings 2 observations · 2024-07-12 → 2024-07-12 ?
By subsystem
By severity
- 5 — Critical: 1
- 2 — Minor: 1
- Repeat observations: 0
Most severe findings
-
Computer control of master formula records
"Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."
-
Records not made readily available to FDA
"Records associated with drug product components, production and control and within the retention period for such records, were not made readily available for authorized inspection."
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Oct 30, 2026
Company Signals 3 articles
Company announcements, not verified evidence. They do not change any score.
Cohance Lifesciences brokerage view: Investec initiates Buy, ₹560 target, CDMO discount - Business Upturn
Cohance Lifesciences brokerage view: Investec initiates Buy, ₹560 target, CDMO discount Business Upturn
Cohance Lifesciences appoints Abhimanyu Ojha as Chief Financial Officer - BioSpectrum India
Cohance Lifesciences appoints Abhimanyu Ojha as Chief Financial Officer BioSpectrum India
Cohance Lifesciences receives voluntary 'Strong' ESG rating from Crisil - scanx.trade
Cohance Lifesciences receives voluntary 'Strong' ESG rating from Crisil scanx.trade
Frequently Asked Questions About Cohance Lifesciences
How many FDA inspections does Cohance Lifesciences have on record?
CDMO Signal tracks 6 FDA inspections for Cohance Lifesciences, sourced from the FDA inspection database. See the full inspection history above.
Has Cohance Lifesciences received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Cohance Lifesciences.
Does Cohance Lifesciences have a CDMO Signal Score?
Not yet. Cohance Lifesciences is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Cohance Lifesciences for a manufacturing program?
Use the free AI matchmaker to compare Cohance Lifesciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Porton Pharma Solutions
Chongqing, China
Small Molecule API, Peptides & Oligos, Finished Dosage Forms, ADC / Bioconjugation, Cell & Gene Therapy
Anthem Biosciences
India
Small Molecule API, Peptides & Oligos, Biologics
Neuland Laboratories
Hyderabad, Telangana, India
Small Molecule API, Peptides & Oligos
Shilpa Medicare
India (registered sites)
Small Molecule API, Oral Solid Dose, Sterile Fill-Finish, Biologics, Peptides & Oligos
Lupin Manufacturing Solutions
Mumbai, India
Small Molecule API, Peptides, High-Potency APIs, Microbial Fermentation, ADC / Bioconjugation
Compare Cohance Lifesciences with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.